nach oben

Erschienen in:

22.03.2023 | Original Article

Pink1-/- Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease

verfasst von: Maryann N. Krasko, John Szot, Karolina Lungova, Linda M. Rowe, Glen Leverson, Cynthia A. Kelm-Nelson, Michelle R. Ciucci

Erschienen in: Dysphagia | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Early motor and non-motor signs of Parkinson disease (PD) include dysphagia, gastrointestinal dysmotility, and constipation. However, because these often manifest prior to formal diagnosis, the study of PD-related swallow and GI dysfunction in early stages is difficult. To overcome this limitation, we used the Pink1-/- rat, a well-established early-onset genetic rat model of PD to assay swallowing and GI motility deficits. Thirty male rats were tested at 4 months (Pink1-/- = 15, wildtype (WT) control = 15) and 6 months (Pink1-/- = 7, WT = 6) of age; analogous to early-stage PD in humans. Videofluoroscopy of rats ingesting a peanut-butter-barium mixture was used to measure mastication rate and oropharyngeal and pharyngoesophageal bolus speeds. Abnormal swallowing behaviors were also quantified. A second experiment tracked barium contents through the stomach, small intestine, caecum, and colon at hours 0–6 post-barium gavage. Number and weight of fecal emissions over 24 h were also collected. Compared to WTs, Pink1-/- rats showed slower mastication rates, slower pharyngoesophageal bolus speeds, and more abnormal swallowing behaviors. Pink1-/- rats demonstrated significantly delayed motility through the caecum and colon. Pink1-/- rats also had significantly lower fecal pellet count and higher fecal pellet weight after 24 h at 6 months of age. Results demonstrate that swallowing dysfunction occurs early in Pink1-/- rats. Delayed transit to the colon and constipation-like signs are also evident in this model. The presence of these early swallowing and GI deficits in Pink1-/- rats are analogous to those observed in human PD.

Kelm-Nelson CA, Lechner SA, Lettenberger SE, Kaldenberg TAR, Pahapill NK, Regenbaum A, Ciucci MR Pink1−/− rats are a useful tool to study early Parkinson disease. Brain Commun. 2021; 3: fcab077, https://doi.org/10.1093/braincomms/fcab077.

Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: a review. JAMA—J Am Med Assoc. 2020;323:548–60. https://doi.org/10.1001/jama.2019.22360.CrossRef

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601. https://doi.org/10.1002/mds.26424.CrossRefPubMed

Sioka C, Fotopoulos A, Kyritsis AP. Recent advances in PET imaging for evaluation of Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37:1594–603. https://doi.org/10.1007/s00259-009-1357-9.CrossRefPubMed

Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 2009;73:1752–8. https://doi.org/10.1212/WNL.0b013e3181c34af5.CrossRefPubMedPubMedCentral

Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of parkinson’s disease. Am J Epidemiol. 2011;174:546–51. https://doi.org/10.1093/aje/kwr119.CrossRefPubMedPubMedCentral

O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord. 2008;23:101–6. https://doi.org/10.1002/mds.21813.CrossRefPubMed

Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. 2016;31:24–32. https://doi.org/10.1007/s00455-015-9671-9.CrossRefPubMed

Kashihara K Weight loss in Parkinson’s disease. J Neurol. 2006; 2537: 2006, 253, vii38–vii41, https://doi.org/10.1007/S00415-006-7009-0.

10.

Findley LJ. The economic impact of Parkinson’s disease. Park Relat Disord. 2007;13:S8–12. https://doi.org/10.1016/j.parkreldis.2007.06.003.CrossRef

11.

Farri A, Accornero A, Burdese C. Social importance of dysphagia: its impact on diagnosis and therapy. Acta Otorhinolaryngol Ital. 2007;27:83–6.PubMedPubMedCentral

12.

Plowman-Prine EK, Sapienza CM, Okun MS, Pollock SL, Jacobson C, Wu SS, Rosenbek JC. The relationship between quality of life and swallowing in Parkinson’s disease. Mov Disord. 2009;24:1352–8. https://doi.org/10.1002/mds.22617.CrossRefPubMedPubMedCentral

13.

Kwon M, Lee J-H. Oro-pharyngeal dysphagia in Parkinson’s disease and related movement disorders. J Mov Disord. 2019;12:152–60. https://doi.org/10.14802/jmd.19048.CrossRefPubMedPubMedCentral

14.

Tjaden K. Speech and swallowing in Parkinsonʼs disease. Top Geriatr Rehabil. 2008;24:115–26. https://doi.org/10.1097/01.TGR.0000318899.87690.44.CrossRefPubMedPubMedCentral

15.

Kalf JG, de Swart BJM, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18:311–5. https://doi.org/10.1016/j.parkreldis.2011.11.006.CrossRefPubMed

16.

Singer RB. Mortality in patients with Parkinson’s disease treated with dopa. J Insur Med. 1992;24:126–7.PubMed

17.

Gorell JM, Johnson CC, Rybicki BA. Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44:1865–8. https://doi.org/10.1212/wnl.44.10.1865.CrossRefPubMed

18.

Fernandez HH, Lapane KL Predictors of mortality among nursing home residents with a diagnosis of Parkinson’s disease. Med Sci Monit. 2002; 8: CR241–6.

19.

Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, Rodriguez R, Romrell J, Pitts T, Wheeler-Hegland KM, Sapienza CM. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology. 2010;75:1912–9. https://doi.org/10.1212/WNL.0b013e3181fef115.CrossRefPubMedPubMedCentral

20.

Curtis JA, Molfenter S, Troche MS. Predictors of residue and airway invasion in Parkinson’s disease. Dysphagia. 2020;35:220–30. https://doi.org/10.1007/s00455-019-10014-z.CrossRefPubMed

21.

Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson’s disease. World J Gastroenterol. 2016;22:5742–52. https://doi.org/10.3748/wjg.v22.i25.5742.CrossRefPubMedPubMedCentral

22.

Przuntek H, Müller T, Riederer P Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm 2004; 1112 2004; 111, 201–216, https://doi.org/10.1007/S00702-003-0102-Y.

23.

Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol. 2008;15:14–20. https://doi.org/10.1111/j.1468-1331.2008.02056.x.CrossRefPubMed

24.

Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625–39. https://doi.org/10.1016/S1474-4422(15)00007-1.CrossRefPubMed

25.

Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, Yoshino H, Asahina M, Kobayashi S, Hassin-Baer S, et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol. 2004;56:424–7. https://doi.org/10.1002/ana.20251.CrossRefPubMed

26.

Li Y, Tomiyama H, Sato K, Hatano Y, Yoshino H, Atsumi M, Kitaguchi M, Sasaki S, Kawaguchi S, Miyajima H, et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology. 2005;64:1955–7. https://doi.org/10.1212/01.WNL.0000164009.36740.4E.CrossRefPubMed

27.

Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC, Ahmad SO, Sunkin SM, Walker D, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson’s disease. Neurobiol Dis. 2014;70:190–203. https://doi.org/10.1016/j.nbd.2014.06.009.CrossRefPubMed

28.

Yang KM, Blue KV, Mulholland HM, Kurup MP, Kelm-Nelson CA, Ciucci MR. Characterization of oromotor and limb motor dysfunction in the DJ1 -/- model of Parkinson disease. Behav Brain Res. 2018;339:47–56. https://doi.org/10.1016/j.bbr.2017.10.036.CrossRefPubMed

29.

Grant LM, Kelm-Nelson CA, Hilby BL, Blue KV, Paul Rajamanickam ES, Pultorak JD, Fleming SM, Ciucci MR. Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson’s disease. J Neurosci Res. 2015;93:1713–27. https://doi.org/10.1002/jnr.23625.CrossRefPubMedPubMedCentral

30.

Krasko MN, Hoffmeister JD, Schaen-Heacock NE, Welsch JM, Kelm-Nelson CA, Ciucci MR Rat Models of Vocal Deficits in Parkinson’s Disease. Brain Sci. 2021; 11: 925 https://doi.org/10.3390/BRAINSCI11070925.

31.

Kelm-Nelson CA, Trevino MA, Ciucci MR. Quantitative analysis of catecholamines in the Pink1 −/− rat model of early-onset Parkinson’s Disease. Neuroscience. 2018;379:126–41. https://doi.org/10.1016/j.neuroscience.2018.02.027.CrossRefPubMed

32.

Hoffmeister JD, Kelm-Nelson CA, Ciucci MR Quantification of brainstem norepinephrine relative to vocal impairment and anxiety in the Pink1-/- rat model of Parkinson disease. Behav. Brain Res. 2021; 414: 113514, https://doi.org/10.1016/j.bbr.2021.113514.

33.

Glass TJ, Kelm-Nelson CA, Szot JC, Lake JM, Connor NP, Ciucci MR Functional characterization of extrinsic tongue muscles in the Pink1-/- rat model of Parkinson disease. PLoS One 2020;15: e0240366, https://doi.org/10.1371/journal.pone.0240366.

34.

Glass TJ, Kelm-Nelson CA, Russell JA, Szot JC, Lake JM, Connor NP, Ciucci MR. Laryngeal muscle biology in the Pink1/ rat model of Parkinson disease. J Appl Physiol. 2019;126:1326–34. https://doi.org/10.1152/japplphysiol.00557.2018.CrossRefPubMedPubMedCentral

35.

Cullen KP, Grant LM, Kelm-Nelson CA, Brauer AFL, Bickelhaupt LB, Russell JA, Ciucci MR. Pink1 −/− rats show early-onset swallowing deficits and correlative brainstem pathology. Dysphagia. 2018;33:749–58. https://doi.org/10.1007/s00455-018-9896-5.CrossRefPubMedPubMedCentral

36.

Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211, https://doi.org/10.1016/S0197-4580(02)00065-9.

37.

Russell JA, Ciucci MR, Hammer MJ, Connor NP. Videofluorographic assessment of deglutitive behaviors in a rat model of aging and parkinson disease. Dysphagia. 2013;28:95–104. https://doi.org/10.1007/s00455-012-9417-x.CrossRefPubMed

38.

Cullins MJ, Connor NP. Reduced tongue force and functional swallowing changes in a rat model of post stroke dysphagia. Brain Res. 2019;1717:160–6. https://doi.org/10.1016/j.brainres.2019.04.023.CrossRefPubMedPubMedCentral

39.

Rowe LM, Connor NP, Russell JA Respiratory-swallow coordination in a rat model of chemoradiation. Head Neck 2021, hed.26782, https://doi.org/10.1002/hed.26782.

40.

Cabezos PA, Vera G, Castillo M, Fernández-Pujol R, Martín MI, Abalo R Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci Basic Clin 2008: 141: 54–65, https://doi.org/10.1016/j.autneu.2008.05.004.

41.

Bakke M, Larsen SL, Lautrup C, Karlsborg M. Orofacial function and oral health in patients with Parkinson’s disease. Eur J Oral Sci. 2011;119:27–32. https://doi.org/10.1111/j.1600-0722.2010.00802.x.CrossRefPubMed

42.

Ali GN, Wallace KL, Schwartz R, DeCarle DJ, Zagami AS, Cook IJ. Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson’s disease. Gastroenterology. 1996;110:383–92. https://doi.org/10.1053/gast.1996.v110.pm8566584.CrossRefPubMed

43.

Melo A, Monteiro L. Swallowing improvement after levodopa treatment in idiopathic Parkinson’s disease: lack of evidence. Parkinsonism Relat Disord. 2013;19:279–81. https://doi.org/10.1016/J.PARKRELDIS.2012.11.017.CrossRefPubMed

44.

Barikroo A, Carnaby G, Crary M. Effects of age and bolus volume on velocity of hyolaryngeal excursion in healthy adults. Dysphagia. 2015;30:558–64. https://doi.org/10.1007/s00455-015-9637-y.CrossRefPubMed

45.

Chi-Fishman G, Sonies BC. Effects of systematic bolus viscosity and volume changes on hyoid movement kinematics. Dysphagia. 2002;17:278–87. https://doi.org/10.1007/s00455-002-0070-7.CrossRefPubMed

46.

Butler SG, Stuart A, Castell D, Russell GB, Koch K, Kemp S Effects of age, gender, bolus condition, viscosity, and volume on pharyngeal and upper esophageal sphincter pressure and temporal measurements during swallowing. J Speech Lang Hear Res 2009; 52: 240–253, https://doi.org/10.1044/1092-4388(2008/07-0092).

47.

Hoffman MR, Ciucci MR, Mielens JD, Jiang JJ, McCulloch TM. Pharyngeal swallow adaptations to bolus volume measured with high-resolution manometry. Laryngoscope. 2010;120:2367–73. https://doi.org/10.1002/lary.21150.CrossRefPubMedPubMedCentral

48.

Jungheim M, Kallusky J, Ptok M. Effect of bolus volume on pharyngeal swallowing dynamics evaluated with small high-resolution manometry catheters. Laryngorhinootologie. 2017;96:112–7. https://doi.org/10.1055/S-0042-118231.CrossRefPubMed

49.

Nagaya M, Kachi T, Yamada T, Igata A. Videofluorographic study of swallowing in Parkinson’s disease. Dysphagia. 1998;13:95–100. https://doi.org/10.1007/PL00009562.CrossRefPubMed

50.

Bird MR, Woodward MC, Gibson EM, Phyland DJ, Fonda D. Asymptomatic swallowing disorders in elderly patients with parkinson’s disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing. 1994;23:251–4. https://doi.org/10.1093/ageing/23.3.251.CrossRefPubMed

51.

Miller N, Noble E, Jones D, Burn D. Hard to swallow: Dysphagia in Parkinson’s disease. Age Ageing. 2006;35:614–8. https://doi.org/10.1093/ageing/afl105.CrossRefPubMed

52.

Khoshbin K, Hassan A, Camilleri M. Cohort study in parkinsonism: delayed transit, accelerated gastric emptying, and prodromal dysmotility. Neurol Clin Pract. 2021;11:e407–13. https://doi.org/10.1212/CPJ.0000000000001003.CrossRefPubMedPubMedCentral

53.

Dutkiewicz J, Szlufik S, Nieciecki M, Charzyńska I, Królicki L, Smektała P, Friedman A. Small intestine dysfunction in Parkinson’s disease. J Neural Transm. 2015;122:1659–61. https://doi.org/10.1007/s00702-015-1442-0.CrossRefPubMed

54.

Jost WH, Schrank B. Defecatory disorders in de novo Parkinsonians—Colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr. 1998;110:535–7.PubMed

55.

Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin Wochenschr. 1991;69:906–9. https://doi.org/10.1007/BF01798536.CrossRefPubMed

56.

Sakakibara R, Odaka T, Uchiyama T, Asahina M, Yamaguchi K, Yamaguchi T, Yamanishi T, Hattori T. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74:268–72. https://doi.org/10.1136/jnnp.74.2.268.CrossRefPubMedPubMedCentral

57.

Knudsen K, Haase AM, Fedorova TD, Bekker AC, Ostergaard K, Krogh K, Borghammer P. Gastrointestinal Transit Time in Parkinson’s Disease Using a Magnetic Tracking System. J Parkinsons Dis. 2017;7:471–9. https://doi.org/10.3233/JPD-171131.CrossRefPubMed

58.

Knudsen K, Fedorova TD, Bekker AC, Iversen P, Østergaard K, Krogh K, Borghammer P. Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson’s disease: A colon transit and volume study. J Parkinsons Dis. 2017;7:359–67. https://doi.org/10.3233/JPD-161050.CrossRefPubMed

59.

Natale G, Kastsiushenka O, Fulceri F, Ruggieri S, Paparelli A, Fornai F. MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut. Brain Res. 2010;1355:195–206. https://doi.org/10.1016/j.brainres.2010.07.076.CrossRefPubMed

60.

Fornai M, Pellegrini C, Antonioli L, Segnani C, Ippolito C, Barocelli E, Ballabeni V, Vegezzi G, Al Harraq Z, Blandini F, et al. Enteric dysfunctions in experimental Parkinson’s disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats. J Pharmacol Exp Ther. 2016;356:434–44. https://doi.org/10.1124/jpet.115.228510.CrossRefPubMed

61.

Greene JG, Noorian AR, Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson’s disease. Exp Neurol. 2009;218:154–61. https://doi.org/10.1016/j.expneurol.2009.04.023.CrossRefPubMedPubMedCentral

62.

Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S, Greene JG. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp Neurol. 2007;207:4–12. https://doi.org/10.1016/j.expneurol.2007.05.010.CrossRefPubMedPubMedCentral

63.

Zhu HC, Zhao J, Luo CY, Li QQ. Gastrointestinal dysfunction in a Parkinson’s disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus. J Mol Neurosci. 2012;47:15–25. https://doi.org/10.1007/s12031-011-9560-0.CrossRefPubMed

64.

Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM. Constipation in Parkinson’s disease: Objective assessment and response to Psyllium. Mov Disord. 1997;12:946–51. https://doi.org/10.1002/mds.870120617.CrossRefPubMed

65.

Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis. 2012;47:258–67. https://doi.org/10.1016/j.nbd.2012.04.009.CrossRefPubMedPubMedCentral

66.

Ellett LJ, Hung LW, Munckton R, Sherratt NA, Culvenor J, Grubman A, Furness JB, White AR, Finkelstein DI, Barnham KJ, et al. Restoration of intestinal function in an MPTP model of Parkinson’s Disease. Sci Rep. 2016;6:1–11. https://doi.org/10.1038/srep30269.CrossRef

67.

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415–55. https://doi.org/10.1016/0022-510X(73)90175-5.CrossRefPubMed

68.

Betarbet R, Sherer TB, Timothy Greenamyre J. Animal models of Parkinson’s disease. BioEssays. 2002;24:308–18. https://doi.org/10.1002/bies.10067.CrossRefPubMed

69.

Wang E, Kompoliti K, Jiang JJ, Goetz CG. An instrumental analysis of laryngeal responses to apomorphine stimulation in Parkinson disease. J Med Speech Lang Pathol. 2000;8:175–86.

70.

Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson’s disease. Neurology. 2000;54:458–62. https://doi.org/10.1212/wnl.54.2.458.CrossRefPubMed

71.

Klingelhoefer L, Reichmann H. Parkinson’s disease as a multisystem disorder. J Neural Transm. 2017;124:709–13. https://doi.org/10.1007/s00702-017-1692-0.CrossRefPubMed

72.

Macchi B, Paola R, Marino-Merlo F, Felice M, Cuzzocrea S, Mastino A. Inflammatory and cell death pathways in brain and peripheral blood in Parkinson’s disease. CNS Neurol Disord - Drug Targets. 2015;14:313–24. https://doi.org/10.2174/1871527314666150225124928.CrossRefPubMed

73.

Chau KY, Ching HL, Schapira AHV, Cooper JM. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: Relevance to Parkinson’s disease pathogenesis. J Neurochem. 2009;110:1005–13. https://doi.org/10.1111/j.1471-4159.2009.06191.x.CrossRefPubMed

74.

Keane PC, Kurzawa M, Blain PG, Morris CM. Mitochondrial dysfunction in Parkinson’s disease. Parkinsons Dis. 2011. https://doi.org/10.4061/2011/716871.CrossRefPubMedPubMedCentral

75.

Moon HE, Paek SH. Mitochondrial Dysfunction in Parkinson’s Disease. Exp Neurobiol. 2015;24:103–16. https://doi.org/10.5607/en.2015.24.2.103.CrossRefPubMedPubMedCentral

76.

Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103:627-641.e7. https://doi.org/10.1016/j.neuron.2019.05.035.CrossRefPubMedPubMedCentral

77.

Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease - The gut-brain axis and environmental factors. Nat Rev Neurol. 2015;11:625–36. https://doi.org/10.1038/nrneurol.2015.197.CrossRefPubMed

78.

Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517–36. https://doi.org/10.1007/s00702-002-0808-2.CrossRefPubMed

79.

Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s Disease? Evidence from 3 cases. Mov Disord. 2012;27:716–9. https://doi.org/10.1002/mds.25020.CrossRefPubMed

80.

Braak H, De Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006;396:67–72. https://doi.org/10.1016/j.neulet.2005.11.012.CrossRefPubMed

81.

Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord. 2012;27:709–15. https://doi.org/10.1002/mds.23838.CrossRefPubMed

82.

Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, Wang ZY, Roybon L, Melki R, Li JY. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014;128:805–20. https://doi.org/10.1007/s00401-014-1343-6.CrossRefPubMed

83.

Beach TG, Adler CH, Sue LI, Vedders L, Lue LF, White CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689–702. https://doi.org/10.1007/s00401-010-0664-3.CrossRefPubMedPubMedCentral

84.

Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–34. https://doi.org/10.1007/s00441-004-0956-9.CrossRefPubMed

85.

Braak H, Tredici K Del Neuroanatomy and pathology of sporadic Parkinson’s disease; 2008; Vol. 215;.

86.

Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337–41. https://doi.org/10.1001/archneur.60.3.337.CrossRefPubMed

87.

Espay AJ, Lewitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement. Mov Disord. 2014;29:1710–9. https://doi.org/10.1002/mds.26048.CrossRefPubMed

88.

LeWitt PA. Norepinephrine: the next therapeutics frontier for Parkinson’s disease. Transl Neurodegener. 2012;1:1–4. https://doi.org/10.1186/2047-9158-1-4/TABLES/1.CrossRef

89.

Vazey EM, Aston-Jones G The emerging role of norepinephrine in cognitive dysfunctions of Parkinson’s disease. Front Behav Neurosci 2012; 0: 48, https://doi.org/10.3389/fnbeh.2012.00048.

90.

Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84:774–83. https://doi.org/10.1136/jnnp-2011-301817.CrossRefPubMed

91.

Rommelfanger KS, Weinshenker D. Norepinephrine: the redheaded stepchild of Parkinson’s disease. Biochem Pharmacol. 2007;74:177–90. https://doi.org/10.1016/J.BCP.2007.01.036.CrossRefPubMed

92.

Breton-Provencher V, Drummond GT, Sur M. Locus coeruleus norepinephrine in learned behavior: anatomical modularity and spatiotemporal integration in targets. Front Neural Circuits. 2021;15:46. https://doi.org/10.3389/fncir.2021.638007.CrossRef

93.

Sciolino NR, Hsiang M, Mazzone CM, Wilson LR, Plummer NW, Amin J, Smith KG, McGee CA, Fry SA, Yang CX et al. Natural locus coeruleus dynamics during feeding. Sci Adv 2022; 8: eabn9134, https://doi.org/10.1126/sciadv.abn9134.

94.

Hoffmeister JD, Kelm-Nelson CA, Ciucci MR, Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. Behav Brain Res 2022; 41: 113642, https://doi.org/10.1016/j.bbr.2021.113642.

95.

Samuels E, Szabadi E. Functional Neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function Part I: principles of functional organisation. Curr Neuropharmacol. 2008;6:235–53. https://doi.org/10.2174/157015908785777229.CrossRefPubMedPubMedCentral

96.

Natale G, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Parkinson’s disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol Motil. 2008;20:741–9. https://doi.org/10.1111/j.1365-2982.2008.01162.x.CrossRefPubMed

97.

Loane C, Wu K, Bain P, David J, Piccini P, Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology. 2013;80:1850–5. https://doi.org/10.1212/WNL.0b013e318292a31d.CrossRefPubMedPubMedCentral

98.

Kish SJ. Biochemistry of Parkinson’s disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson’s disease? Adv Neurol. 2003;91:39–49.PubMed

99.

Tohgi H, Abe T, Takahashi S, Takahashi J, Hamato H. Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett. 1993;150:71–4. https://doi.org/10.1016/0304-3940(93)90111-W.CrossRefPubMed

100.

Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003;60:1223–9. https://doi.org/10.1001/archneur.60.9.1223.CrossRefPubMed

101.

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain. 2008;131:120–31. https://doi.org/10.1093/brain/awm239.CrossRefPubMed

102.

Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–45. https://doi.org/10.1016/S1474-4422(06)70373-8.CrossRefPubMed

103.

Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov Disord. 2006;21:115–6. https://doi.org/10.1002/mds.20666.CrossRefPubMed

104.

Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson’s disease: on movement, mood, and madness. Mov Disord. 2009;24:1255–66. https://doi.org/10.1002/mds.22473.CrossRefPubMed

105.

Beattie DT, Smith JAM. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:181–203. https://doi.org/10.1007/s00210-008-0276-9.CrossRefPubMed

106.

Haney MM, Sinnott J, Osman KL, Deninger I, Andel E, Caywood V, Mok A, Ballenger B, Cummings K, Thombs L, et al. Mice lacking brain-derived serotonin have altered swallowing function. Otolaryngol—Head Neck Surg (United States). 2019;161:468–71. https://doi.org/10.1177/0194599819846109.CrossRef

107.

Erspamer V. Pharmacology of indole-alkylamines. Pharmacol Rev. 1954;6:425–87.PubMed

108.

Martin AM, Young RL, Leong L, Rogers GB, Spencer NJ, Jessup CF, Keating DJ. The diverse metabolic roles of peripheral serotonin. Endocrinology. 2017;158:1049–63. https://doi.org/10.1210/en.2016-1839.CrossRefPubMed

109.

Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003;2:107–16. https://doi.org/10.1016/S1474-4422(03)00307-7.CrossRefPubMed

110.

Barker JR, Thomas CF, Behan M. Serotonergic projections from the caudal raphe nuclei to the hypoglossal nucleus in male and female rats. Respir Physiol Neurobiol. 2009;165:175–84. https://doi.org/10.1016/j.resp.2008.11.008.CrossRefPubMed

111.

Behan M, Moeser AE, Thomas CF, Russell JA, Wang H, Leverson GE, Connor NP The effect of tongue exercise on serotonergic input to the hypoglossal nucleus in young and old rats. J Speech Lang Hear Res 2012; 55: 919–929, https://doi.org/10.1044/1092-4388(2011/11-0091).

112.

Jean A. Brain stem control of swallowing: neuronal network and cellular mechanisms. Physiol Rev. 2001;81:929–69. https://doi.org/10.1152/physrev.2001.81.2.929.CrossRefPubMed

113.

Zheng L-F, Liu S, Zhou L, Zhang X-L, Yu X, Zhu J-X Dopamine and Gastrointestinal Motility. In: Dopamine in the Gut; Springer, Singapore, 2021; 133–202.

114.

Singaram C, Gaumnitz EA, Torbey C, Ashraf W, Quigley EMM, Sengupta A, Pfeiffer R. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet. 1995;346:861–4. https://doi.org/10.1016/S0140-6736(95)92707-7.CrossRefPubMed

115.

Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson’s disease. J Neurol. 2002;249:138–45. https://doi.org/10.1007/PL00007856.CrossRefPubMed

Titel: Pink1-/- Rats Demonstrate Swallowing and Gastrointestinal Dysfunction in a Model of Prodromal Parkinson Disease
verfasst von: Maryann N. Krasko
John Szot
Karolina Lungova
Linda M. Rowe
Glen Leverson
Cynthia A. Kelm-Nelson
Michelle R. Ciucci
Publikationsdatum: 22.03.2023
Verlag: Springer US
Erschienen in: Dysphagia / Ausgabe 5/2023
Print ISSN: 0179-051X
Elektronische ISSN: 1432-0460
DOI: https://doi.org/10.1007/s00455-023-10567-0

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Swallow Impairment in Parkinson’s Disease: Revelations from High-Resolution Videomanometry

Surface Electromyography for Evaluating the Effect of Aging on the Coordination of Swallowing Muscles

Effects of Age and Lingual-Palatal Pressure Levels on Submental Surface Electromyography Measures

Quantifying Impairments in Swallowing Safety and Efficiency in Progressive Supranuclear Palsy and Parkinson’s Disease